

SASTASUNDAR VENTURES LIMITED

(Formerly Microsec Financial Services Limited)

Azimganj House, 2nd Floor,
7 Abanindra Nath Thakur Sarani (Formerly Camac Street),
Kolkata - 700 017, India. Tel: +91 33 2282 9330; Fax: +91 33 2282 9335
Email: info@sastasundar.com; Website: www.sastasundarventures.com
CIN: L65993WB1989PLC047002

Date: 05-03-2019

To
The General Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Tower
Dalal Street, Mumbai — 400 001

Manager - Listing
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Mumbai — 400 051

Dear Sir,

Ref: Script Code: 533259 and Symbol: SASTASUNDR


Re: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Regulations”)

We would like to inform you that Sastasundar Ventures Limited (the Company) has signed a Share Purchase Agreement (“the Agreement”) today i.e. 5th March, 2019 with Sastasundar Healthbuddy Limited, a subsidiary Company (the Acquirer), to sell and transfer the entire stake held by the Company in Genu Path Labs Limited, a wholly owned subsidiary company.

The details as required under regulation 30 of the SEBI Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 are given in Annexure –A to this letter.

For Sastasundar Ventures Limited

For SASTASUNDAR VENTURES LIMITED



Biplab Kumar Mani
Company Secretary & Compliance officer
ACS-19883

SASTASUNDAR VENTURES LIMITED

(Formerly Microsec Financial Services Limited)

Azimganj House, 2nd Floor,
7 Abanindra Nath Thakur Sarani (Formerly Camac Street),
Kolkata - 700 017, India. Tel: +91 33 2282 9330; Fax: +91 33 2282 9335
Email: info@sastasundar.com; Website: www.sastasundarventures.com
CIN: L65993WB1989PLC047002

Annexure- A**DISCLOSURE FOR THE PROPOSED SALE OF 100 % EQUITY INVESTMENT HELD IN GENU PATH LABS LIMITED, A WHOLLY OWNED SUBSIDIARY COMPANY**

1	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year	<u>Name of the Wholly Owned Subsidiary:</u> Genu Path Labs Limited <u>Revenue for the year ended 31st March, 2018-</u> Rs. 2,30,044 <u>Net Worth as on 31st March, 2018:</u> Rs. 2,89,95,534/-
2	Date on which the agreement for sale has been entered into	The Agreement executed on today i.e. 5 th March, 2019.
3.	The expected date of completion of sale/disposal	The expected date of completion of Divestment of Equity Investment held in Wholly Owned Subsidiary shall be subject to fulfilment of conditions as specified in the agreement.
4.	Consideration received from such sale/disposal	The consideration for divestment of Equity Investment held in Wholly Owned Subsidiary is INR 6.00 crores. The consideration will be received as per the terms of the Agreement.
5.	Brief details of buyers and whether any of the buyers belong to the promoter/promoter group/group companies. If yes, details thereof	The name of the buyer is Sastasundar Healthbuddy Limited, a subsidiary Company of the Company.
6.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length."	Yes, the transaction falls within the Related Party Transaction. The transaction is being done based on independent valuation report.
7.	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.	Not Applicable

For SASTASUNDAR VENTURES LIMITED

Deplab K. Nani
Company Secretary